Table 1 Clinical characteristics in overall cohort and the three subgroups

Age (y)

44.1 ± 14.7/43.0

(17-92)

44.2 ± 12.0/44.0 (23-72)

42.2 ± 13.8/42.0 (22-78)

44.1 ± 14.3/43

(17-92)

Follow-up time (y)

7.3/5.6

(0.40-32.20)

5.0/3.1

(0.25-25.90)

8.8/6.2

(0.80-29.00)

7.1/5.3

(0.25-32.20)

Preoperative diagnosis

Benign

174 (76.0%)

26 (78.8%)

11 (84.6%)

211 (76.7%)

Undetermined

10 (4.4%)

2 (6.1%)

0 (0%)

12 (4.4%)

Suspected malignant

40 (17.5%)

5 (15.2%)

1 (7.7%)

46 (16.7%)

Obvious malignant

5 (2.2%)

0 (0%)

1 (7.7%)

6 (2.2%)

Mass size (cm)

7.4 ± 4.5/6.4

(1.8 – 50.0)

6.7 ± 3.0/6.7

(2.0-18.40)

7.1 ± 3.2/7.3

(3.0-14.6)

7.3 ± 4.3/6.4

(1.8 – 50.0)

Carcinoma size (cm)

NA

0.44 (0.2-1.3)

(10 cases)

0.6 (0.3-1.2)

(3 cases)

NA

Elevated tumor makers

57 (24.9%)

9 (27.3%)

6 (46.2%)

72 (26.2%)

CA 125 (case/median)

47 / 62.0

7 / 169.0

5 / 89.9

59 / 71.2

CA125 (range, U/ml)

35.8 – 2263.5

45.7 – 1129.0

67.0-103.0

35.8 – 2263.5

CA19-9 (case/median)

20 / 97.0

2 / 241.4

NA

22 / 97.0

CA19-9 (range, U/ml)

41.4-480.0

91.4 – 391.3

NA

41.4-480.0

Ascites

39 (17.0%)

4 (12.1%)

1 (7.7%)

44 (16.0%)

Side of lesions (ovary)

Left

95 (41.5%)

18 (54.5%)

8 (61.5%)

121 (44.0%)

Right

131 (57.2%)

15 (45.5%)

2 (15.4%)

146 (53.1%)

Bilateral

2 (0.9%)

0 (0%)

0 (0%)

2 (0.7%)

Metastatic

1 (0.4%)

0 (0%)

3 (23.1%)

6 (2.2%)